A Flight-Forward Nrf2 Research Program

A claim tested in sequence

Nrf2 remains a research target for spaceflight countermeasure development. It is not yet an established path from food to human-flight protection. A staged Gastronaut program can measure that distance honestly, link by link, from crop chemistry to a mission-relevant human response.

The bounded claim is this: under defined ORCA growing conditions, a selected crop and preparation method can deliver a measured bioactive exposure suitable for testing Nrf2 pathway engagement. Composition does not establish exposure. Exposure does not establish pathway engagement. Pathway engagement does not establish protection. Preserving those distinctions is part of the work, not a delay to it.

Why the sequence matters

The oxidative-stress corpus contains many positive results from simulated microgravity and terrestrial irradiation, followed by mixed flight results and null findings in a human analog antioxidant trial. The repaired exact comparison found reported countermeasure benefit in 31 of 34 T4 simulated-microgravity records and 3 of 12 T3 human ground-analog records, an odds ratio of 31.0 with Fisher exact p = 3.5 x 10^-5 (Gastronaut 2026, GAS-OXS-CORR-2026-01). This is an association between evidence tier and reported benefit, not a causal estimate of model validity or treatment efficacy.

The Nrf2 signal came from Bion-M 2, a 30-day high-latitude orbital mouse study. Its preprint reports that pharmacological Nrf2 activation with omaveloxolone preserved hindlimb muscle mass at ground-control levels and protected visceral organs. The study measured 73 endpoints, did not state a multiplicity correction, and supplied no human evidence. Diet also changed the physiological response, placing nutrition inside the experimental system rather than beyond it (Andreev-Andrievskiy et al.).

This signal merits investigation of Nrf2 activation in flight. It does not make omaveloxolone equivalent to a crop-derived compound, a mouse endpoint equivalent to a human outcome, or orbital exposure equivalent to a deep-space mission. Each bridge must carry its own evidence.

Gate 1: establish the food

The crop comes first. Gastronaut would select a crop, cultivar, developmental stage, and preparation associated with an Nrf2-relevant bioactive. The analyte, assay, sampling plan, acceptable range, and batch criteria would be prespecified.

Every sample would retain its ORCA environmental record. Light spectrum and dose, temperature, humidity, carbon dioxide, root-zone conditions, nutrient formulation, microbial status, harvest time, and plant stress exposure could influence composition. The result would be a reproducible concentration distribution under named conditions. It would not be an efficacy finding.

Gate 2: follow the delivered exposure

Harvest concentration is not crew exposure. This gate measures what survives storage, processing, preparation, and consumption, including degradation, serving size, and adherence.

Mass-balance data would follow plant tissue to the consumed portion, with storage duration, preparation method, quality-control sampling, crew handling, and waste defined alongside it. If the compound cannot pass through a practical food process, the program learns that before biological efficacy becomes the governing question.

Gate 3: separate arrival from engagement

Bioavailability and pathway engagement answer separate questions. The protocol would test whether the delivered compound or its metabolites reach the participant, then whether they engage the intended pathway. Prespecified pharmacokinetic sampling and a bounded Nrf2-responsive biomarker panel would keep exposure biomarkers distinct from downstream oxidative-damage markers.

Spaceflight biomarkers vary by tissue, duration, and mission phase, which makes this separation consequential. In six Mir crewmembers, an oxidative-damage marker decreased in flight and increased after flight. In 23 crewmembers, ferritin correlated with 8-OHdG at r = 0.53, pointing to iron status as a related mechanism and potential stratification variable (Stein, Leskiw, and Stein; Zwart, Morgan, and Smith).

Gate 4: test one function in one tissue

Pathway engagement would permit a functional-benefit test; it would not prove benefit. The study would select one tissue and one mission-relevant endpoint because the literature argues against a single systemic antioxidant outcome. BuOE produced a retinal benefit in one mouse flight study and no measurable muscle rescue in another. Success in one organ cannot speak for the whole body (Braun and Fajardo; Mao et al.).

A ground analog may serve dose selection and instrumentation, provided its conclusion remains an analog conclusion. The Toulouse trial of 20 men marks that boundary. Its nutritional antioxidant cocktail did not mitigate several outcomes across a 60-day bed-rest campaign, despite positive evidence for antioxidant agents elsewhere in the literature (Kermorgant et al. 2024).

Gate 5: test transfer in the integrated environment

Flight transfer completes the sequence. Microgravity and radiation can move biological pathways in different directions, and a spaceflight gene-expression response can differ from tail suspension or denervation. A proposed flight protocol would keep radiation, gravity, cabin environment, diet, activity, mission duration, and recovery timing beside the biological endpoint (Barravecchia and Angeloni 2022; Nikawa et al.).

Randomization, comparator selection, sample-size logic, endpoint hierarchy, missing-data rules, and multiplicity control would be established before exposure. The result could support, refine, or reject the countermeasure claim. Each outcome would leave the next decision better grounded.

The decision now

Gastronaut can make this sequence executable. ORCA can be developed as a controlled production and observation environment, while Gastronaut’s evidence system maintains continuity among crop conditions, product chemistry, delivered dose, biological response, and operational burden.

ORCA remains a ground-stage system at approximately TRL 3 to 4, with no flight or lunar operating history. Confidence is moderate that Nrf2 merits flight-forward investigation and low for equivalence among a crop-derived compound, pharmacological activation, and a human-flight outcome. Every gate is designed to test one part of that uncertainty.

NASA would receive a protocol that reserves flight resources for candidates whose composition, stability, exposure, and pathway questions have been answered. Investors would see milestones tied to reduced technical uncertainty. Gastronaut would advance its claim at the pace of its evidence.

The immediate step is a reproducibility study for crop chemistry and delivered exposure, designed to support later pathway and flight-transfer tests. The claim is smaller than human protection, and more useful at this stage. The rest of the program depends on whether it can be established with care.

References

Andreev-Andrievskiy, A., et al. “Bion-M 2 Biosatellite: Multisystem Mouse Responses to 30 Days in High-Latitude Orbit as a Deep-Space Analog.” bioRxiv, 2026, doi:10.64898/2026.05.03.722490. Preprint.

Barravecchia, I., and D. Angeloni. “Microgravity Inhibits Autophagy in Human Capillary Endothelial Cells in Space Flight.” Autophagy Reports, vol. 1, no. 1, 2022, pp. 337-340, doi:10.1080/27694127.2022.2102363.

Braun, J. L., and V. A. Fajardo. “Spaceflight Increases Sarcoplasmic Reticulum Ca2+ Leak and This Cannot Be Counteracted with BuOE Treatment.” npj Microgravity, 2024, doi:10.1038/s41526-024-00419-y.

Gastronaut. Oxidative Stress and Radiation: Evidence Synthesis. Evidence version frozen 21 Aug. 2026. Research synthesis.

Gastronaut. Gastronaut Oxidative-Stress Evidence Correction Record. GAS-OXS-CORR-2026-01, 24 Aug. 2026.

Kermorgant, M., et al. “The Effects of Antioxidant Cocktail on Ophthalmological Changes Induced by a 60-Day Head-Down Bed Rest in a Randomized Trial.” Life, vol. 14, no. 12, 2024, article 1598, doi:10.3390/life14121598.

Mao, X. W., et al. “Evidence of Spaceflight-Induced Adverse Effects on Photoreceptors and Retinal Function in the Mouse Eye.” International Journal of Molecular Sciences, 2023, doi:10.3390/ijms24087362.

Nikawa, T., et al. “Skeletal Muscle Gene Expression in Space-Flown Rats.” FASEB Journal, 2004, doi:10.1096/fj.03-0419fje.

Stein, T. P., M. J. Leskiw, and T. P. Stein. “Oxidant Damage During and After Spaceflight.” American Journal of Physiology: Endocrinology and Metabolism, 2000, doi:10.1152/ajpendo.2000.278.3.E375.

Zwart, S. R., J. L. Morgan, and S. M. Smith. “Iron Status and Its Relations with Oxidative Damage and Bone Loss During Long-Duration Space Flight on the International Space Station.” American Journal of Clinical Nutrition, 2013, doi:10.3945/ajcn.112.056465.